10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2012

o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______

Commission file number 0-27119

SCIVANTA MEDICAL CORPORATION

(Exact name of registrant as specified in its charter)

Nevada	22-2436721
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

215 Morris Avenue, Spring Lake, New Jersey 07762

(Address of principal executive offices)

(732) 282-1620

(Issuer’s telephone number)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  YesxNo¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes   x     No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.  See definitions of “large accelerated filer,” “accelerated filer,” and smaller reporting company in Rule 12b-2 of the Securities Exchange Act of 1934.

Large accelerated filer      ¨	Accelerated filer                      ¨
Non-accelerated filer        ¨             (Do not check if a smaller reporting company)	Smaller reporting company    x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).  Yes¨Nox

As of September 17, 2012, there were 31,116,913 shares of the registrant’s common stock, par value $.001 per share, outstanding.

SCIVANTA MEDICAL CORPORATION

INDEX TO FORM 10-Q

Page

PART I FINANCIAL INFORMATION

Item 1. Financial Statements 1

Balance Sheets (unaudited) as of July 31, 2012 and October 31, 2011 2

Statements of Operations (unaudited) for the three and nine months ended July 31, 2012 and 2011 3

Statements of Cash Flows (unaudited for the nine months ended July 31, 2012 and 2011 4

Notes to the Unaudited Financial Statements 5

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 12

Item 3. Quantitative and Qualitative Disclosures About Market Risk 16

Item 4. Controls and Procedures 16

PART II OTHER INFORMATION

Item 1. Legal Proceedings 17

Item 1A. Risk Factors 17

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 17

Item 3. Defaults Upon Senior Securities 17

Item 4. Mine Safety Disclosures 17

Item 5. Other Information 17

Item 6. Exhibits 17

Signatures 18

Index of Exhibits  E-1

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain information included in this quarterly report on Form 10-Q and other filings of the registrant under the Securities Act of 1933, as amended (the “Securities Act”), and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as well as information communicated orally or in writing between the dates of such filings, contains or may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act.  All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objections of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing.

Forward-looking statements may include the words “may”, “could”, “estimate”, “intend”, “continue”, “believe”, “expect” or “anticipate” or other similar words.  These forward-looking statements present our estimates and assumptions only as of the date of this report.  Except as may be required under applicable securities laws, we do not intend, and undertake no obligation, to update any forward-looking statement. Additionally, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 most likely do not apply to our forward-looking statements because we are considered a penny stock issuer.  You should, however, consult further disclosures we make in future filings of our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.  The registrant is under no duty to update any of the forward-looking statements contained herein after the date this quarterly report on Form 10-Q is submitted to the Securities and Exchange Commission (the “SEC”).

PART I .  FINANCIAL INFORMATION

Item 1.               Financial Statements

The balance sheet as of July 31, 2012, the related statements of operations for the three and nine months ended July 31, 2012 and 2011 and cash flows for the nine months ended July 31, 2012 and 2011 for Scivanta Medical Corporation (“Scivanta” or the “Company”) included in Item 1, have been prepared by us, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures required under accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted from the following financial statements pursuant to the rules and regulations of the SEC.  In the opinion of management, the accompanying financial statements include all adjustments, which are of a normal and recurring nature, necessary to present fairly our financial position and results of operations.  It is suggested that the following financial statements be read in conjunction with the financial statements and notes thereto included in the registrant’s annual report on Form 10-K for the fiscal year ended October 31, 2011.

The results of operations for the three and nine months ended July 31, 2012 and 2011, respectively, are not necessarily indicative of the results of the entire fiscal year or for any other period.

1

Scivanta Medical Corporation

Balance Sheets

(Unaudited)

	July 31, 2012			October 31, 2011
Assets
Current assets:
Cash	$	17,994		$	46,245
Grant receivable		--			131,979
Prepaid expenses		9,271			6,037
Total current assets	$	27,265		$	184,261
Liabilities and Stockholders’ Deficiency
Current liabilities:
Accounts payable	$	227,793		$	208,912
Accounts payable - related party		66,868			41,302
Accrued expenses		81,835			81,794
Accrued compensation		225,627			225,627
Notes payable		110,412			105,000
Convertible debentures		25,000			75,000
Total current liabilities		737,535			737,635
Convertible debentures		275,000			275,000
Total liabilities		1,012,535			1,012,635
Commitments and contingencies
Stockholders' deficiency:
Common stock, $.001 par value; 100,000,000 shares authorized; 31,116,913 and 30,564,543 shares issued and outstanding, respectively		31,117			30,564
Additional paid-in capital		22,343,225			22,264,583
Accumulated deficit		(23,359,612	)		(23,123,521	)
Total stockholders' deficiency		(985,270	)		(828,374	)
Total liabilities and stockholders' deficiency	$	27,265		$	184,261
The accompanying notes are an integral part of these financial statements.

2

Scivanta Medical Corporation

Statements of Operations

(Unaudited)

	Three Months Ended July 31,						Nine Months Ended July 31,
	2012			2011			2012			2011
Grant revenue	$	--		$	--		$	--		$	--
Operating expenses (income):
Research and development		5,540			6,930			14,430			41,281
General and administrative		62,209			171,411			180,562			534,561
Loss from operations		(67,749	)		(178,341	)		(194,992	)		(575,842	)
Interest expense		(6,217	)		(6,821	)		(19,349	)		(17,141	)
Loss on conversion of convertible debentures		--			--			(21,750	)		--
Net loss	$	(73,966	)	$	(185,162	)	$	(236,091	)	$	(592,983	)
Net loss per common share, basic and diluted	$	0.00		$	(0.01	)	$	(0.01	)	$	(0.02	)
Weighted average number of common shares outstanding, basic and diluted		31,116,913			30,358,021			30,983,366			30,071,869
The accompanying notes are an integral part of these financial statements.

3

Scivanta Medical Corporation

Statements of Cash Flows

(Unaudited)

	Nine Months Ended July 31,
	2012			2011
Cash flows from operating activities:
Net loss	$	(236,091	)	$	(592,983	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation expense		3,716			16,782
License fees		--			26,562
Loss on conversion of convertible debentures		21,750			--
Changes in operating assets and liabilities:
Grant receivable		131,979			112,500
Prepaid expenses		12,633			22,847
Accounts payable		18,881			45,426
Accounts payable - related party		25,566			(5,044	)
Accrued expenses		3,770			5,457
Accrued compensation		--			299,929
Net cash used in operating activities		(17,796	)		(68,524	)
Cash flows from financing activities:
Proceeds from sale of common stock, net of offering costs		--			22,125
Proceeds from issuance of convertible debenture		--			100,000
Repayment of notes payable		(10,455	)		(42,248	)
Refund of proceeds from deposit on stock purchase		--			(100,000	)
Restricted cash – stock purchase		--			100,000
Net cash (used in) provided by financing activities		(10,455	)		79,877
(Decrease) increase in cash		(28,251	)		11,353
Cash - beginning of period		46,245			81,365
Cash - end of period	$	17,994		$	92,718
Supplemental disclosure of cash flow information:
Cash paid for interest	$	579		$	563
Noncash financing activities:
Issuance of 552,370 shares of common stock as payment of $50,000 of principal and $3,729 of interest due on      convertible debentures	$	53,729		$	--
Issuance of note payable as payment for insurance premium	$	15,867		$	15,867
Issuance of 500,000 shares of common stock as payment for interest due on convertible debentures	$	--		$	20,000
The accompanying notes are an integral part of these financial statements.

4

Scivanta Medical Corporation

Notes to the Unaudited Financial Statements

1.   Basis of Presentation

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.  The Company has incurred significant recurring operating losses, negative cash flows from operations, has a working capital deficiency and an accumulated deficit of $23,359,612 as of July 31, 2012.  The Company has not paid the $105,000 that was due to Hickey on July 31, 2012 and, as a result, the Amended and Restated License Agreement can be placed in default by the Licensor in accordance with the default provisions of such agreement (see Notes 2 and 4).  The Company also has no lending relationships with commercial banks and is dependent on the completion of a financing involving the private placement of its securities in order to continue operations.  The recent economic slowdown has made financing more difficult to obtain.  These factors raise substantial doubt about the Company’s ability to continue as a going concern.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The Company continues to seek equity and/or debt investors and from time to time engages placement agents to assist the Company in this initiative.  The Company has reduced operating expenses and effective November 1, 2011, each of the Company’s officers agreed to waive the annual base salary due to them and each of the Company’s directors agreed to waive the annual retainer and meeting fees due to them until the Company is able to raise sufficient capital that would provide the Company with the ability to pay cash compensation to its officers and directors.  The Company has also deferred the payment of $200,000 of accrued compensation due to its officers, deferred the payment of $17,000 to its directors and a former director and deferred certain other vendor payments until the Company secures sufficient additional financing.

While the Company is pursuing the opportunities and actions described above, there can be no assurance that it will be successful in its efforts.  If the Company is unable to secure additional capital, it will explore other strategic alternatives, including, but not limited to, the sale of the Company.  Any additional equity financing may result in substantial dilution to our stockholders (see Note 10).

2.   Amended and Restated SCMS License Agreement

On February 14, 2011, the Company entered into an Amended and Restated technology license agreement (the “Amended and Restated License Agreement”) with The Research Foundation of State University of New York, for and on behalf of the University at Buffalo (the “Foundation”), Donald D. Hickey, M.D. (“Hickey”) and Clas E. Lundgren (“Lundgren”).  The Foundation, Hickey and Lundgren shall be collectively referred to herein as the “Licensor.”  The Amended and Restated License Agreement replaced the technology license agreement entered into by the Company and the Licensor on November 10, 2006, as amended.

5

Pursuant to the Amended and Restated License Agreement, the Licensor has granted Scivanta the exclusive world-wide rights to develop, manufacture and distribute the SCMS, a minimally invasive two-balloon esophageal catheter system used to monitor cardiac performance.  The term of the Amended and Restated License Agreement ends on the later of (a) the expiration date of the last to expire patent right related to the SCMS, which is currently May 1, 2027, or (b) 17 years from the sale of the first licensed product on a country by country basis.

Under the Amended and Restated License Agreement, Scivanta agreed to pay Hickey $135,000, which was paid or required to be paid as follows:  (a) a cash payment of $30,000 was made to Hickey on June 3, 2011 and (b) a cash payment of $105,000 was due to Hickey on the date that is thirty (30) days after the first commercial sale of a product utilizing the licensed technology, but no later than July 31, 2012.  The Company has not paid the $105,000 due to Hickey and, as a result, the Amended and Restated License Agreement can be placed in default by the Licensor in accordance with the default provisions discussed below.

Scivanta is required to pay the Licensor a royalty of 5% of annual net sales, as defined in the Amended and Restated License Agreement, subject to certain reductions as detailed in the Amended and Restated License Agreement.  Beginning with the first full year of sales of the SCMS in the United States and for two years thereafter, Scivanta is required to pay an annual minimum royalty of $100,000 to the Licensor against which any royalty on net sales paid in the same calendar year for sales in the United States will be credited.  Further, beginning with the first full year of sales of the SCMS outside the United States and for two years thereafter, Scivanta is required to pay an annual minimum royalty of $100,000 to the Licensor against which any royalty on net sales paid in the same calendar year for sales outside the United States will be credited.  The Company is also required to pay the Licensor 25% of all sublicensing revenue, as defined in the Amended and Restated License Agreement, received by the Company in connection with the Company’s sublicense of the rights granted to the Company under the Amended and Restated License Agreement.

The Amended and Restated License Agreement, as amended by the Addendum, also requires Scivanta to use commercially reasonable efforts to develop and market the SCMS within certain timeframes, subject to specified exceptions.  If Scivanta materially fails to perform any covenant, condition or undertaking of the Amended and Restated License Agreement, including the failure to make any payments when due, the Licensor may give written notice of such default to Scivanta.  If Scivanta should fail to cure such default within ninety (90) days of notice of such default, then the Licensor, at its option, may terminate the Amended and Restated License Agreement.  Further, the Amended and Restated License Agreement contains standard provisions regarding indemnification and patent prosecution.

3.   Related Party Transactions

David R. LaVance, the Company’s Chairman, President and Chief Executive Officer, and Thomas S. Gifford, the Company’s Executive Vice President, Chief Financial Officer and Secretary, are principals of Century Capital Associates LLC (“Century Capital”).   Effective February 1, 2007, the Company and Century Capital entered into a sublease agreement pursuant to which the Company rents office space approximating 2,000 square feet inside Century Capital’s existing offices.  In addition, the Company rents office furniture and other equipment from Century Capital.  The sublease agreement has a month to month term that requires sixty days written notice to terminate and a monthly rental fee of $5,000.  The Company is responsible for all operating costs associated with the office space, including utilities, maintenance and property taxes.

6

During the three and nine months ended July 31, 2012, the Company was billed $17,730 and $54,297, respectively, pursuant to the terms of the sublease agreement.  As of July 31, 2012, the Company owed Century Capital $65,000 for rent and $1,868 for other expenses, which amounts are included in accounts payable – related party.  During the three and nine months ended July 31, 2011, the Company was billed $16,005 and $51,913, respectively, pursuant to the terms of the sublease agreement.

4.   Notes Payable

Note Payable – Hickey

Under the Amended and Restated License Agreement (see Note 2), a cash payment of $105,000 was due to Hickey on July 31, 2012.  The Company has not paid the $105,000 due to Hickey and, as a result, the Amended and Restated License Agreement can be placed in default by the Licensor in accordance with the default provisions of such agreement.  The Company recorded the $105,000 due to Hickey as a component of notes payable.

Note Payable – Insurance

On January 4, 2012, the Company entered into a finance agreement with Imperial Credit Corporation (“Imperial”).  Pursuant to the terms of this finance agreement, Imperial loaned the Company the principal amount of $15,867, which amount would accrue interest at a rate of 9.3% per annum, in order to partially fund the payment of the premium of the Company’s director and officer liability insurance.  The finance agreement requires the Company to make nine monthly payments of $1,832, including interest, with the first payment due on January 31, 2012.  For the three and nine months ended July 31, 2012, the Company recorded a total of $167 and $579, respectively, of interest expense related to this finance agreement.  As of July 31, 2012, the outstanding principal balance related to this finance agreement was $5,412, which is recorded as a component of notes payable.

5.   Convertible Debentures

February 2007 Convertible Debentures

On February 8, 2007, the Company closed on a private placement of 8% convertible debentures dated February 1, 2007 totaling $250,000 (the “February 2007 Debentures”).  In January 2010, the holders agreed to amend the February 2007 Debentures.  Pursuant to this amendment, the holders agreed to a new maturity date of January 31, 2012, extending the term of the February 2007 Debentures for an additional two year period.

7

On January 11, 2012, the Company issued 500,000 shares of common stock at $0.10 per share as full payment of $50,000 of outstanding principal on certain February 2007 Debentures and 52,370 shares of common stock at per share prices ranging between $0.07 and $0.08 as full payment of $3,729 of accrued and unpaid interest related to those February 2007 Debentures.  Due to the reduction in the conversion price, the Company recorded a loss on conversion of these February 2007 Debentures of $21,750.

Effective January 31, 2012, certain holders of February 2007 Debentures with an aggregate outstanding principal amount of $175,000, agreed to amend such February 2007 Debentures by extending the maturity date to January 31, 2014.  In addition, effective January 31, 2012, a holder of a February 2007 Debenture with an outstanding principal amount of $25,000 agreed to amend his February 2007 Debenture by extending the maturity date to July 31, 2012.  The Company has not made payment on this February 2007 Debenture and as a result, such obligation can be placed in default by the holder.

For the three and nine months ended July 31, 2012, the Company recorded a total of $4,033 and $12,764, respectively, of interest expense related to the February 2007 Debentures.  For the three and nine months ended July 31, 2011, the Company recorded a total of $5,000 and $15,000, respectively, of interest expense related to the February 2007 Debentures.  As of July 31, 2012, $24,035 of interest due on the February 2007 Debentures was accrued and is included as a component of accrued expenses.

May 2011 Convertible Debenture

On May 20, 2011, the Company issued an 8% convertible debenture in the amount of $100,000 to an institutional investor (the “May 2011 Debenture”).  For the three and nine months ended July 31, 2012, the Company recorded a total of $2,017 and $6,006 of interest expense related to the May 2011 Debenture.  As of July 31, 2012, $9,601 of interest due on the May 2011 Debenture was accrued and is included as a component of accrued expenses.

6.   Stock-Based Compensation

The Company accounts for stock-based payments to employees in accordance with Accounting Standards Codification 718, “Stock Compensation” (“ASC 718”).  During the three and nine months ended July 31, 2012, the Company recorded employee stock-based compensation expense of $0 and $3,716, respectively, which have been included in general and administrative expense.  During the three and nine months ended July 31, 2011, the Company recorded employee stock-based compensation expense of $4,221 and $16,782, respectively,  which have been included in general and administrative expense.

7.   Net Loss Per Common Share

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period.  Diluted earnings per share reflect, in periods in which they have a dilutive effect, the impact of common shares issuable upon exercise of stock options and warrants and conversion of convertible debt that are not deemed to be anti-dilutive.  The dilutive effect of the outstanding stock options and warrants is computed using the treasury stock method.

8

For the three and nine months ended July 31, 2012, diluted net loss per share did not include the effect of 2,495,332 shares of common stock issuable upon the exercise of outstanding options, 930,000 shares of common stock issuable upon the exercise of outstanding warrants and 4,166,666 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive.

For the three and nine months ended July 31, 2011, diluted net loss per share did not include the effect of 2,495,332 shares of common stock issuable upon the exercise of outstanding options, 4,046,750 shares of common stock issuable upon the exercise of outstanding warrants and 4,375,000 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive.

8.   Stockholders’ Equity

Stock Option Plans

The Company currently has two stock option plans in place:  the 2002 Equity Incentive Plan and the 2007 Equity Incentive Plan (collectively, the “Equity Incentive Plans”).  The 2002 Equity Incentive Plan was approved by the stockholders on July 5, 2002.  The aggregate number of shares of common stock which could have been awarded under the 2002 Equity Incentive Plan was 2,000,000.  As of July 31, 2012, options to purchase 1,470,000 shares of the Company’s common stock were outstanding under the 2002 Equity Incentive Plan.  As a result of the adoption of the Company’s 2007 Equity Incentive Plan, no further awards are permitted under the 2002 Equity Incentive Plan.

On May 31, 2007, the stockholders approved the Company’s 2007 Equity Incentive Plan.  The 2007 Equity Incentive Plan was placed into effect in order to encourage and enable employees and directors of the Company to acquire or increase their holdings of the Company’s common stock and to promote these individual’s interests in the Company thereby enhancing the efficiency, soundness, profitability, growth and stockholder value of the Company.  The 2007 Equity Incentive Plan provides for awards in the form of restricted shares, incentive stock options, non-qualified stock options and stock appreciation rights.  The aggregate number of shares of common stock which may be awarded under the 2007 Equity Incentive Plan is 3,000,000, subject to adjustment as provided in the 2007 Equity Incentive Plan.  As of July 31, 2012, options to purchase 1,025,332 shares of the Company’s common stock were outstanding under the 2007 Equity Incentive Plan and up to 1,974,668 shares of the Company’s common stock remain available for awards under the 2007 Equity Incentive Plan.

Stock option awards under the Equity Incentive Plans were granted at prices as determined by the Company’s compensation committee, but such prices were not less than the fair market value of the Company's common stock on the date of grant.  Stock options granted and outstanding include only non-qualified options and vest over a period of up to five years and have a maximum term of ten years from the date of grant.

9

A summary of stock option transactions for employees and directors under the Equity Incentive Plans during the nine months ended July 31, 2012 is as follows:

	Stock Option Shares		Weighted Average Exercise Price Per Common Share		Aggregate Intrinsic Value
Outstanding at October 31, 2011		2,495,332	$	0.16	$	5,800
Granted during the period		--		--
Exercised during the period		--		--
Expired during the period		--		--
Outstanding at July 31, 2012		2,495,332	$	0.16	$	700
Exercisable at July 31, 2012		2,495,332	$	0.16	$	700
Exercisable at October 31, 2011		2,328,664	$	0.16	$	5,800

Information with respect to outstanding options and options exercisable as of July 31, 2012 that were granted to employees is as follows:

		Stock Options Outstanding						Stock Options Exercisable
Exercise Price		Number of Shares Available Under Outstanding Stock Options		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)		Number of Shares Available for Purchase Under Outstanding Stock Options		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)
$	0.02		35,000	$	0.02		2.4		35,000	$	0.02		2.4
$	0.08		335,000	$	0.08		2.1		335,000	$	0.08		2.1
$	0.14		1,025,332	$	0.14		5.2		1,025,332	$	0.14		5.2
$	0.20		1,100,000	$	0.20		4.5		1,100,000	$	0.20		4.5
			2,495,332	$	0.16		4.4		2,495,332	$	0.16		4.4

10

Warrants to Purchase Common Stock

A summary of warrant transactions during the nine months ended July 31, 2012 is as follows:

	Warrant Shares			Weighted Average Exercise Price Per Common Share		Aggregate Intrinsic Value
Outstanding at October 31, 2011		4,046,750		$	0.12	$	10,000
Issued during the period		--			--
Exercised during the period		--			--
Expired during the period		(3,116,750	)	$	0.12
Outstanding at July 31, 2012		930,000		$	0.12	$	--
Exercisable at July 31, 2012		930,000		$	0.12	$	--
Exercisable at October 31, 2011		4,046,750		$	0.12	$	10,000

Information with respect to outstanding warrants and warrants exercisable at July 31, 2012 is as follows:

		Warrants Outstanding						Warrants Exercisable
Range of Exercise Prices		Number of Shares Available Under Outstanding Warrants		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)		Number of Shares Available for Purchase Under Outstanding Warrants		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)
$	0.04		200,000	$	0.04		1.8		200,000	$	0.04		1.8
$	0.10 - 0.13		535,000	$	0.12		0.6		535,000	$	0.12		0.6
$	0.20 - 0.25		195,000	$	0.21		1.0		195,000	$	0.21		1.0
			930,000	$	0.12		0.9		930,000	$	0.12		0.9

10. Subsequent Events

On August 15, 2012, the Company issued an 8% convertible debenture to an institutional investor (the “August 2012 Debenture”).  The gross proceeds received in connection with this private placement were $100,000.  The August 2012 Debenture has a three year term maturing on August 15, 2015 and bears interest at a rate of 8% per annum.  Interest is payable in annual installments, beginning on August 15, 2013, in cash or, at the option of the Company, in shares of the Company’s common stock.  If the Company elects to pay the interest in shares of the Company’s common stock, the number of shares issued as payment will be equal to the quotient of the unpaid interest divided by the market price of the Company’s common stock as defined in the August 2012 Debenture.

11

The entire principal amount of the August 2012 Debenture is convertible at any time into shares of the Company’s common stock at the option of the holder at a conversion price of $0.04 per share.  In addition, at the option of the Company and subject to certain restrictions provided in the August 2012 Debenture, the entire principal amount of the August 2012 Debenture is convertible into shares of the Company’s common stock at a conversion price of $0.04 per share upon the occurrence of: (a) a merger or acquisition of the Company or (b) the closing of a financing involving the Company’s common stock that results in gross proceeds to the Company, on a cumulative basis, of at least $600,000.  The quoted market price of the Company’s common stock as of August 15, 2012 was $0.04 per share.

An aggregate amount of 2,500,000 shares of the Company’s common stock can be issued pursuant to the August 2012 Debenture. The Company will use the proceeds received in this private placement for working capital purposes.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Background

Scivanta is a Nevada corporation headquartered in Spring Lake, New Jersey.  Scivanta currently does not sell any products or services.

On November 10, 2006, we acquired the exclusive world-wide rights to develop, manufacture and distribute the Scivanta Cardiac Monitoring System (the “SCMS”), a minimally invasive two-balloon esophageal catheter system used to monitor cardiac performance.  The SCMS is currently in the development stage.

The SCMS will provide the primary measurements of cardiac performance, including left atrial pressure, which is a crucial measurement in monitoring cardiac challenged patients.  The essential hardware, software and catheter components for the SCMS have been completed.  Scivanta currently has a fully assembled SCMS device that has been used in the initial clinical trial.  The two major items remaining in the development of the SCMS are the completion of the clinical trials and the design and engineering of the production model of the SCMS.

We will not be able to complete the clinical trials or the design and engineering of the production model of the SCMS without obtaining additional cash through equity and/or debt financing or through corporate partnerships.  We continue to pursue potential investors and from time to time engage placement agents to assist us in this endeavor.  No assurances can be given that we will be able to obtain sufficient capital to finish the development of the SCMS through any corporate partnerships and/or through equity and/or debt financing.  In addition, no assurances can be given that if we successfully develop and market the SCMS, such product will become profitable.

12

Critical Accounting Policies and Estimates

The discussion and analysis of the Company’s financial condition and results of operations are based upon the interim financial statements contained elsewhere herein, which have been prepared in accordance with U.S. GAAP.  The preparation of these financial statements required us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities.  On an on-going basis, we evaluate our estimates, including those related to contingencies and litigation.  We based our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.  Actual results may differ from these estimates under different assumptions or conditions.

The critical accounting estimates that we believe affect the more significant judgments and estimates used in preparation of the financial statements contained elsewhere herein are described in the Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to the Financial Statements included in the Company’s annual report on Form 10-K for the fiscal year ended October 31, 2011.  There have been no material changes to the critical accounting policies.

Results of Operations

Research and Development.  For the three months ended July 31, 2012, research and development expenses were $5,540, as compared to $6,930 for the three months ended July 31, 2011.  The $1,390, or 20%, decrease in research and development expense for the three months ended July 31, 2012 was primarily due to a decrease in patent costs.

For the nine months ended July 31, 2012, research and development expenses were $14,430, as compared to $41,281 for the nine months ended July 31, 2011.  The $26,851, or 65%, decrease in research and development expense for the nine months ended July 31, 2012 was primarily due to a $26,562 decrease in license costs related to the Amended and Restated License Agreement.

The amount of research and development expense to be incurred by us during the fiscal year ending October 31, 2012 will depend upon our ability to secure additional capital through an equity and/or debt financing or corporate partnerships.  In the event that we are able to obtain additional capital sufficient to fund our research and development program, we would expect research and development expenses for the fiscal year ending October 31, 2012 to increase.  If we are unable to obtain additional capital sufficient to fund our research and development program, we would expect research and development expenses for the fiscal year ending October 31, 2012 to remain at current levels.

13

General and Administrative.  For the three months ended July 31, 2012, general and administrative expenses were $62,209, as compared to $171,411 for the three months ended July 31, 2011.  The $109,202, or 64%, decrease in general and administrative expenses for the three months ended July 31, 2012 was primarily due to a $99,830 decrease in employee payroll and related tax and benefit costs primarily related to Messrs. LaVance and Gifford’s agreement with the Company, effective November 1, 2011, to waive salary due to each of them under their respective employment agreements until the Company is able to raise sufficient capital, a $9,000 decrease in director fees related to the directors’ agreement with the Company, effective November 1, 2011, to waive cash compensation due them until the Company is able to raise sufficient capital and a $4,220 decrease in stock based compensation expense primarily related to stock options granted to employees and directors, offset by a $4,065 increase in legal expenses associated with corporate activities.

For the nine months ended July 31, 2012, general and administrative expenses were $180,562, as compared to $534,561 for the nine months ended July 31, 2011.  The $353,999, or 66%, decrease in general and administrative expenses for the nine months ended July 31, 2012 was primarily due to a $306,606 decrease in employee payroll and related tax and benefit costs primarily related to Messrs. LaVance and Gifford’s agreement with the Company, effective November 1, 2011, to waive salary due to each of them under their respective employment agreements until the Company is able to raise sufficient capital, a $27,000 decrease in director fees related to the directors’ agreement with the Company, effective November 1, 2011, to waive cash compensation due them until the Company is able to raise sufficient capital and a $13,065 decrease in stock based compensation expense related to stock options granted to employees and directors.

The amount of general and administrative expense to be incurred by us during the fiscal year ending October 31, 2012 will depend upon our ability to secure additional capital through an equity and/or debt financing or corporate partnerships.  In the event that we are able to obtain additional capital sufficient to fund our development and marketing of the SCMS, we would expect general and administrative expenses for the fiscal year ending October 31, 2012 to increase as we build the administrative infrastructure necessary to support the development and marketing of the SCMS.  If we are unable to obtain additional capital sufficient to fund our development and marketing of the SCMS, we would expect general and administrative expenses for the fiscal year ending October 31, 2012 to decrease as we continue to reduce our operating activities.

Interest Expense.  For the three months ended July 31, 2012, interest expense was $6,217, as compared to $6,821 for the three months ended July 31, 2011.  The $604, or 9%, decrease in interest expense for the three months ended July 31, 2012 was primarily due to a decrease in interest expense associated with the February 2007  Debentures due to the partial conversion to common stock of certain February 2007 Debentures.

For the nine months ended July 31, 2012, interest expense was $19,349, as compared to $17,141 for the nine months ended July 31, 2011.  The $2,208, or 13%, increase in interest expense for the nine months ended July 31, 2012 was primarily due to a $4,428 increase in interest expense associated with the May 2011 Debenture, offset by a $2,236 decrease in interest expense associated with the February 2007  Debentures due to the partial conversion to common stock of certain February 2007 Debentures.

14

Loss on Conversion of Convertible Debentures.  For the three and nine months ended July 31, 2012, the Company recognized a loss of $0 and $21,750, respectively, on the conversion of certain February 2007 Convertible Debentures resulting from a reduction in the conversion price.

Net Loss.  For the three months ended July 31, 2012, the Company had a net loss of $73,966, or $0.00 per share (basic and diluted), as compared to a net loss of $185,162, or $0.01 per share (basic and diluted), for the three months ended July 31, 2011.  The decrease in the net loss was primarily attributable to a $1,390 decrease in research and development expenses and a $108,800 decrease in general and administrative expenses.

For the nine months ended July 31, 2012, the Company had a net loss of $236,091, or $0.01 per share (basic and diluted), as compared to a net loss of $592,983, or $0.02 per share (basic and diluted), for the nine months ended July 31, 2011.  The decrease in the net loss was primarily attributable to a $26,851 decrease in research and development expenses and a $353,999 decrease in general and administrative expenses, offset by a $21,750 loss on the conversion of certain February 2007 Debentures.

Liquidity and Capital Resources

As of July 31, 2012, the Company had working capital deficiency of $710,270 and cash on hand of $17,994.  The $28,251 decrease in cash on hand from October 31, 2011 was primarily due to the Company’s continuing operating expenses offset by the receipt of $131,979 of gross proceeds related to the Qualified Therapeutic Discovery Project (“QTDP”) grant.

During the past several years, the Company has generally sustained recurring losses and negative cash flows from operations.  We currently do not generate any revenue from operations.  Our operations most recently have been funded through a combination of the sale of our convertible debentures and common stock and proceeds received from the QTDP grant.

On August 15, 2012, the Company issued an 8% convertible debenture to an institutional investor.  The gross proceeds received in connection with this private placement were $100,000.

As of September 17, 2012, our cash position was approximately $86,000.  Without any additional financing, we will only be able to continue our administrative operations, on a limited basis, for approximately six months from the filing date of this quarterly report on Form 10-Q.  We have reduced operating expenses and effective November 1, 2011, the Company’s officers agreed to waive the annual base salary due to them and the Company’s directors agreed to waive the annual retainer and meeting fees due to them until the Company is able to raise sufficient capital that would provide the Company with the ability to pay cash compensation to its officers and directors.  The Company has also deferred the payment of $200,000 of accrued compensation due to its officers, deferred the payment of $17,000 to its directors and a former director and deferred certain other vendor payments until the Company secures sufficient additional financing.  Our independent registered public accounting firm included an emphasis of a matter paragraph in its report included in our annual report on Form 10-K for the fiscal year ended October 31, 2011, which expressed substantial doubt about our ability to continue as a going concern.  Our financial statements included herein do not include any adjustments related to this uncertainty.

15

We currently do not have any lending relationships with commercial banks and do not anticipate establishing such relationships in the foreseeable future due to our limited operations and assets.  We believe that our focus should be on obtaining additional capital through the private placement of our securities.  We are pursuing potential equity and/or debt investors and have engaged placement agents to assist us in this initiative.  While we are pursuing the opportunities and actions described above, there can be no assurance that we will be successful in our efforts.  If we are unable to secure additional capital, we will explore other strategic alternatives, including, but not limited to, the sale of the Company.  Any additional equity financing may result in substantial dilution to our stockholders.

Expenditures related to the development of the SCMS are at our discretion.  Assuming that we are successful in obtaining additional financing, we estimate that we could potentially spend approximately $1,000,000 related to the development of the SCMS over the twelve month period following the financing.

Item 3.                    Quantitative and Qualitative Disclosures About Market Risk

Scivanta is a smaller reporting company and is therefore not required to provide this information.

Item 4.                    Controls and Procedures

As required by Rule 13a-15 under the Exchange Act, as of the end of the Company’s last fiscal quarter, the Company carried out an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures.  This evaluation was carried out under the supervision and with the participation of the Company’s management, including the Company’s President and Chief Executive Officer and the Company’s Executive Vice President, Chief Financial Officer and Secretary (Principal Financial and Accounting Officer), who concluded that the Company’s disclosure controls and procedures are effective.  During the Company’s last fiscal quarter, there was no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in the Company reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.  Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in Company reports filed under the Exchange Act is accumulated and communicated to management, including the Company’s Chief Executive Officer and the Chief Financial Officer (Principal Financial and Accounting Officer), as appropriate, to allow timely decisions regarding required disclosure.

16

PART II.  OTHER INFORMATION

Item 1.                    Legal Proceedings

None.

Item 1A.                 Risk Factors

Scivanta is a smaller reporting company and is therefore not required to provide this information.

Item 2.                    Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3.                    Defaults Upon Senior Securities

None.

Item 4.                    Mine Safety Disclosures

Not Applicable.

Item 5.                    Other Information

Under the Amended and Restated License Agreement (see Note 2), a cash payment of $105,000 was due to Hickey on July 31, 2012.  The Company has not paid the $105,000 due to Hickey and, as a result, the Amended and Restated License Agreement can be placed in default by the Licensor in accordance with the default provisions of such agreement.  We are currently in discussions with the Licensor regarding an amendment to the Amended and Restated License Agreement to restructure this payment and address other issues.

Item 6.                    Exhibits

See Index of Exhibits Commencing on Page E-1.

17

SIGNATURES

In accordance with the requirements of the Exchange Act, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

DATE:	SCIVANTA MEDICAL CORPORATION
September 19, 2012	By:	/s/ David R. LaVance
		David R. LaVance
		President and Chief Executive Officer

September 19, 2012	By:	/s/ Thomas S. Gifford
		Thomas S. Gifford
		Executive Vice President,
		Chief Financial Officer and Secretary

18

INDEX OF EXHIBITS

Exhibit

Number Description of Exhibit

3.1 Restated Articles of Incorporation of Scivanta Medical Corporation, formerly Medi-Hut Co., Inc. (the “Company”), which was filed in the Office of the Secretary of State of the State of Nevada on January 23, 2007 (incorporated by reference to Exhibit 3.1 to the Company’s quarterly report on Form 10-QSB for the quarter ended January 31, 2006, filed with the Securities and Exchange Commission (the “SEC”) on January 29, 2007).

3.2 Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s quarterly report on Form 10-QSB for the quarter ended January 31, 2006, filed with the SEC on January 29, 2007).

4.1 Specimen stock certificate representing the Company’s common stock (incorporated by reference to Exhibit 4.1 to the Company’s quarterly report on Form 10-QSB for the quarter ended January 31, 2006, filed with the SEC on January 29, 2007).

4.2 Form of Convertible Debenture, dated as of February 1, 2007, issued to the following persons and in the following amounts:  Jesse H. Austin, III ($50,000); Andrew O. Whiteman and Gwen C. Whiteman, JTWROS ($25,000); Alan Eicoff ($25,000); Jack W. Cumming ($25,000); Scott C. Withrow ($25,000); Terrence McQuade ($25,000); Steven J. Olsen ($25,000); Robert P. Reynolds ($12,500); Chartwell Partners, LLP ($12,500); and Marc G. Robinson and Joshua Goldfarb ($25,000) (incorporated by reference to Exhibit 4.8 to the Company’s quarterly report on Form 10-QSB for the quarter ended January 31, 2007, filed with the SEC on March 14, 2007).

4.3 Form of Addendum to Convertible Debenture, dated as of January 31, 2010, issued to the persons set forth in Exhibit 4.2 (incorporated by reference to Exhibit 4.3 to the Company’s annual report on Form 10-K for the fiscal year ended October 31, 2009, filed with the SEC on January 29, 2010).

4.4 Form of Addendum to Convertible Debenture, dated as of January 31, 2012, issued to certain persons set forth in Exhibit 4.2 (incorporated by reference to Exhibit 4.4 to the Company’s quarterly report on Form 10-Q for the quarter ended January 31, 2012, filed with the SEC on March 16, 2012).

4.5 8% Convertible Debenture, dated as of May 20, 2011, issued to Zanett Opportunity Fund, Ltd. (incorporated by reference to Exhibit 4.4 to the Company’s quarterly report on Form 10-Q for the quarter ended April 30, 2011, filed with the SEC on June 14, 2011).

10.1 The Company’s 2002 Equity Incentive Plan, adopted and effective January 1, 2002 (incorporated by reference to Exhibit B of the Company’s definitive proxy statement, filed with the SEC on June 10, 2002).

10.2 Sublease Agreement, dated February 1, 2007, between the Company and Century Capital Associates LLC (incorporated by reference to Exhibit 10.14 to the Company’s quarterly report on Form 10-QSB for the quarter ended January 31, 2007, filed with the SEC on March 14, 2007).

E-1

Exhibit

Number Description of Exhibit

10.3 Amended and Restated Technology License Agreement between the Company and The Research Foundation of State University of New York for and on behalf of University of Buffalo, and Donald D. Hickey, M.D. and Clas E. Lundgren dated February 14, 2011 (incorporated by reference to Exhibit 10.8 to the Company’s annual report on Form 10-K for the fiscal year ended October 31, 2010, filed with the SEC on February 15, 2011).

10.4 Stock Option Agreement and Notice of Grant, dated February 5, 2007, pursuant to which David R. LaVance was granted a non-qualified stock option to purchase up to 500,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.16 to the Company’s quarterly report on Form 10-QSB for the quarter ended January 31, 2007, filed with the SEC on March 14, 2007).

10.5 Stock Option Agreement and Notice of Grant, dated February 5, 2007, pursuant to which Thomas S. Gifford was granted a non-qualified stock option to purchase up to 500,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.17 to the Company’s quarterly report on Form 10-QSB for the quarter ended January 31, 2007, filed with the SEC on March 14, 2007).

10.9 Company’s 2007 Equity Incentive Plan, adopted and effective May 31, 2007 (incorporated by reference to Appendix to the Company’s definitive proxy statement, filed with the SEC on April 27, 2007).

10.10 Stock Option Agreement and Notice of Grant, dated January 1, 2008, pursuant to which David R. LaVance was granted a non-qualified stock option to purchase up to 100,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.21 to the Company’s current report on Form 8-K filed with the SEC on January 2, 2008).

10.11 Stock Option Agreement and Notice of Grant, dated January 1, 2008, pursuant to which Thomas S. Gifford was granted a non-qualified stock option to purchase up to 100,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.22 to the Company’s current report on Form 8-K filed with the SEC on January 2, 2008).

10.12 Stock Option Agreement and Notice of Grant, dated January 1, 2008, pursuant to which Richard E. Otto was granted a non-qualified stock option to purchase up to 27,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.23 to the Company’s current report on Form 8-K filed with the SEC on January 2, 2008).

E-2

Exhibit

Number Description of Exhibit

10.13 Stock Option Agreement and Notice of Grant, dated January 1, 2008, pursuant to which Lawrence M. Levy was granted a non-qualified stock option to purchase up to 25,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.24 to the Company’s current report on Form 8-K filed with the SEC on January 2, 2008).

10.14 Stock Option Agreement and Notice of Grant, dated January 1, 2008, pursuant to which Anthony Giordano, III was granted a non-qualified stock option to purchase up to 29,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.25 to the Company’s current report on Form 8-K filed with the SEC on January 2, 2008).

10.15 Executive Employment Agreement, dated as of January 1, 2008, between the Company and David R. LaVance (incorporated by reference to Exhibit 10.26 to the Company’s current report on Form 8-K filed with the SEC on January 2, 2008).

10.16 Executive Employment Agreement, dated as of January 1, 2008, between the Company and Thomas S. Gifford (incorporated by reference to Exhibit 10.27 to the Company’s current report on Form 8-K filed with the SEC on January 2, 2008).

10.17 Amendment No. 1 dated as of June 18, 2010 to the Executive Employment Agreement, dated as of January 1, 2008, between the Company and David R. LaVance (incorporated by reference to Exhibit 10.27 to the Company’s quarterly report on Form 10-Q for the quarter ended April 30, 2010, filed with the SEC on June 21, 2010).

10.18 Amendment No. 1 dated as of June 18, 2010 to the Executive Employment Agreement, dated as of January 1, 2008, between the Company and Thomas S. Gifford (incorporated by reference to Exhibit 10.28 to the Company’s quarterly report on Form 10-Q for the quarter ended April 30, 2010, filed with the SEC on June 21, 2010).

10.19 Amendment No. 2 dated as of January 3, 2012 to the Executive Employment Agreement, dated as of January 1, 2008, between the Company and David R. LaVance (incorporated by reference to Exhibit 10.23 to the Company’s annual report on Form 10-KSB for the fiscal year ended October 31, 2011, filed with the SEC on January 30, 2012).

10.20 Amendment No. 2 dated as of January 3, 2012 to the Executive Employment Agreement, dated as of January 1, 2008, between the Company and Thomas S. Gifford (incorporated by reference to Exhibit 10.24 to the Company’s annual report on Form 10-KSB for the fiscal year ended October 31, 2011, filed with the SEC on January 30, 2012).

10.21 Stock Option Agreement and Notice of Grant, dated January 21, 2009, pursuant to which David R. LaVance was granted a non-qualified stock option to purchase up to 250,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.32 to the Company’s annual report on Form 10-KSB for the fiscal year ended October 31, 2008, filed with the SEC on January 29, 2009).

E-3

Exhibit

Number Description of Exhibit

10.22 Stock Option Agreement and Notice of Grant, dated January 21, 2009, pursuant to which Thomas S. Gifford was granted a non-qualified stock option to purchase up to 250,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.33 to the Company’s annual report on Form 10-KSB for the fiscal year ended October 31, 2008, filed with the SEC on January 29, 2009).

10.27 Stock Option Agreement and Notice of Grant, dated January 21, 2009, pursuant to which Richard E. Otto was granted a non-qualified stock option to purchase up to 37,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.34 to the Company’s annual report on Form 10-KSB for the fiscal year ended October 31, 2008, filed with the SEC on January 29, 2009).

10.28 Stock Option Agreement and Notice of Grant, dated January 21, 2009, pursuant to which Lawrence M. Levy was granted a non-qualified stock option to purchase up to 35,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.35 to the Company’s annual report on Form 10-KSB for the fiscal year ended October 31, 2008, filed with the SEC on January 29, 2009).

10.29 Stock Option Agreement and Notice of Grant, dated January 21, 2009, pursuant to which Anthony Giordano, III was granted a non-qualified stock option to purchase up to 39,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.36 to the Company’s annual report on Form 10-KSB for the fiscal year ended October 31, 2008, filed with the SEC on January 29, 2009).

31.1 Section 302 Certification of Chief Executive Officer.

31.2 Section 302 Certification of Chief Financial Officer.

32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.

32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.

E-4

EX-31.1

EXHIBIT 31.1

CERTIFICATION

I, David R. LaVance, certify that:

1.      I have reviewed this report on Form 10-Q of Scivanta Medical Corporation;

2.      Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.      Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.      The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)  Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)  Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.      The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:  September 19, 2012	By:	/s/ David R. LaVance
		David R. LaVance
		President and Chief Executive Officer

EX-31.2

EXHIBIT 31.2

CERTIFICATION

I, Thomas S. Gifford, certify that:

1. I have reviewed this report on Form 10-Q of Scivanta Medical Corporation;

2.      Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.      Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.      The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)  Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)  Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.      The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:  September 19, 2012	By:	/s/ Thomas S. Gifford
		Thomas S. Gifford
		Executive Vice President,
		Chief Financial Officer and Secretary

EX-32.1

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Scivanta Medical Corporation (the “Company”) on Form 10-Q for the period ended July 31, 2012, as filed with the Securities and Exchange Commission (the “Report”), I, David R. LaVance, President and Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)           the Report fully complies with the requirements of §13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, 15 U.S.C. §78m or 78o(d), and,

(2)           the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:  September 19, 2012	By:	/s/ David R. LaVance
		David R. LaVance
		President and Chief Executive Officer

EX-32.2

EXHIBIT 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Scivanta Medical Corporation (the “Company”) on Form 10-Q for the period ended July 31, 2012, as filed with the Securities and Exchange Commission (the “Report”), I, Thomas S. Gifford, Executive Vice President, Chief Financial Officer and Secretary of the Company, do hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)           the Report fully complies with the requirements of §13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, 15 U.S.C. §78m or 78o(d), and,

(2)           the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:  September 19, 2012	By:	/s/ Thomas S. Gifford
		Thomas S. Gifford
		Executive Vice President,
		Chief Financial Officer and Secretary

XML

Stockholders' Equity (Details) (Stock Option [Member], USD $)	9 Months Ended
	Jul. 31, 2012
Stock Option [Member]
Summary of stock option transactions for employees and directors under the Equity Incentive Plans
Stock Option/Warrants Shares, Outstanding Beginning Balance	2,495,332
Weighted Average Exercise Price Per Common Share/Warrants, Outstanding Beginning Balance	$ 0.16
Aggregate Intrinsic Value, Outstanding Stock Option/Warrants beginning balance	$ 5,800
Stock Option/Warrants, Granted during the period
Weighted Average Exercise Price Per Common Share/Warrants, Granted during the period
Stock Option/Warrants, Exercised during the period
Weighted Average Exercise Price Per Common Share/Warrants, Exercised during the period
Stock Option Shares, Expired during the period
Weighted Average Exercise Price Per Common Share/Warrants, Expired during the period
Stock Option/Warrants, Outstanding at July 31, 2012	2,495,332
Weighted Average Exercise Price Per Common Share/Warrants, Outstanding at July 31, 2012	$ 0.16
Aggregate Intrinsic Value, Outstanding Stock Option/Warrants at July 31, 2012	700
Stock Option Shares/Warrants, Exercisable at July 31, 2012	2,495,332
Weighted Average Exercise Price Per Common Share/Warrants, Exercisable at July 31, 2012	$ 0.16
Aggregate Intrinsic Value, Stock Option/Warrants Exercisable at July 31, 2012	700
Stock Option/Warrants, Exercisable at October 31, 2011	2,328,664
Weighted Average Exercise Price Per Common Share/Warrant, Exercisable at October 31, 2011	$ 0.16
Aggregate Intrinsic Value, Stock Option/Warrants Exercisable at October 31, 2011	$ 5,800

XML

Related Party Transactions

9 Months Ended

Jul. 31, 2012

Related Party Transactions [Abstract]

Related Party Transactions

3.   Related Party Transactions

David R. LaVance, the Company’s Chairman, President and Chief Executive Officer, and Thomas S. Gifford, the Company’s Executive Vice President, Chief Financial Officer and Secretary, are principals of Century Capital Associates LLC (“Century Capital”).   Effective February 1, 2007, the Company and Century Capital entered into a sublease agreement pursuant to which the Company rents office space approximating 2,000 square feet inside Century Capital’s existing offices.  In addition, the Company rents office furniture and other equipment from Century Capital.  The sublease agreement has a month to month term that requires sixty days written notice to terminate and a monthly rental fee of $5,000.  The Company is responsible for all operating costs associated with the office space, including utilities, maintenance and property taxes.

During the three and nine months ended July 31, 2012, the Company was billed $17,730 and $54,297, respectively, pursuant to the terms of the sublease agreement.  As of July 31, 2012, the Company owed Century Capital $65,000 for rent and $1,868 for other expenses, which amounts are included in accounts payable – related party.  During the three and nine months ended July 31, 2011, the Company was billed $16,005 and $51,913, respectively, pursuant to the terms of the sublease agreement.

XML

Stockholders' Equity (Details Textual)	9 Months Ended
	Jul. 31, 2012
Stockholders' Equity (Textual)
Number of equity incentive plans	2
Minimum [Member]
Stockholders' Equity (Textual)
Vesting period of options	5 years
Maximum [Member]
Stockholders' Equity (Textual)
Vesting period of options	10 years
The 2002 Equity Incentive Plan [Member]
Stockholders' Equity (Textual)
Aggregate number of shares of common stock which could have been awarded	2,000,000
Stock Options/ Warrants Outstanding, Number of Shares Available Under Outstanding Stock Options	1,470,000
The 2007 Equity Incentive Plan [Member]
Stockholders' Equity (Textual)
Aggregate number of shares of common stock which could have been awarded	3,000,000
Stock Options/ Warrants Outstanding, Number of Shares Available Under Outstanding Stock Options	1,025,332
Common stock remain available for awards	1,974,668

XML

Stockholders' Equity (Details 3) (Warrant [Member], USD $)	9 Months Ended
	Jul. 31, 2012	Oct. 31, 2011
Information with respect to outstanding and exercisable options and warrants
Stock Options/ Warrants Outstanding, Number of Shares Available Under Outstanding Stock Options	930,000
Stock Options/ Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	10 months 24 days
Stock Options/ Warrants Exercisable, Number of Shares Available for Purchase Under Outstanding Stock Options	930,000	4,046,750
Stock Options/ Warrants Exercisable, Weighted Average Exercise Price Per Common Share	$ 0.12	$ 0.12
Stock Options/ Warrants Exercisable, Weighted Average Remaining Contractual Life (Years)	10 months 24 days
0.04 [Member]
Information with respect to outstanding and exercisable options and warrants
Stock Options/ Warrants Outstanding, Number of Shares Available Under Outstanding Stock Options	200,000
Stock Options/ Warrants Outstanding, Weighted Average Exercise Price Per Common Share	$ 0.04
Stock Options/ Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	1 year 9 months 18 days
Range of Exercise Prices, Upper Range Limit	$ 0.04
Stock Options/ Warrants Exercisable, Number of Shares Available for Purchase Under Outstanding Stock Options	200,000
Stock Options/ Warrants Exercisable, Weighted Average Exercise Price Per Common Share	$ 0.04
Stock Options/ Warrants Exercisable, Weighted Average Remaining Contractual Life (Years)	1 year 9 months 18 days
0.10 - 0.13 [Member]
Information with respect to outstanding and exercisable options and warrants
Range of Exercise Prices, Lower Range Limit	$ 0.10
Stock Options/ Warrants Outstanding, Number of Shares Available Under Outstanding Stock Options	535,000
Stock Options/ Warrants Outstanding, Weighted Average Exercise Price Per Common Share	$ 0.12
Stock Options/ Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	7 months 6 days
Range of Exercise Prices, Upper Range Limit	$ 0.13
Stock Options/ Warrants Exercisable, Number of Shares Available for Purchase Under Outstanding Stock Options	535,000
Stock Options/ Warrants Exercisable, Weighted Average Exercise Price Per Common Share	$ 0.12
Stock Options/ Warrants Exercisable, Weighted Average Remaining Contractual Life (Years)	7 months 6 days
0.20 - 0.25 [Member]
Information with respect to outstanding and exercisable options and warrants
Range of Exercise Prices, Lower Range Limit	$ 0.20
Stock Options/ Warrants Outstanding, Number of Shares Available Under Outstanding Stock Options	195,000
Stock Options/ Warrants Outstanding, Weighted Average Exercise Price Per Common Share	$ 0.21
Stock Options/ Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	1 year 0 months
Range of Exercise Prices, Upper Range Limit	$ 0.25
Stock Options/ Warrants Exercisable, Number of Shares Available for Purchase Under Outstanding Stock Options	195,000
Stock Options/ Warrants Exercisable, Weighted Average Exercise Price Per Common Share	$ 0.21
Stock Options/ Warrants Exercisable, Weighted Average Remaining Contractual Life (Years)	1 year 0 months

XML

Subsequent Events (Details) (USD $)	9 Months Ended
	Jul. 31, 2012	Jul. 31, 2011	Jan. 04, 2012
Subsequent events (Textual)
Interest rate on convertible debentures			9.30%
Proceed from issuance of common stock		$ 22,125
August 2012 Debenture [Member] | Forecast [Member]
Subsequent events (Textual)
Interest rate on convertible debentures	8.00%
Gross proceeds from Issuance of Private Placement	100,000
Debt instrument, maturity date	Aug. 15, 2015
Convertible debenture maturity term	3 years
Conversion price of convertible debt	$ 0.04
Convertible debt conversion description	Upon the occurrence of: (a) a merger or acquisition of the Company or (b) the closing of a financing involving the Company's common stock that results in gross proceeds to the Company, on a cumulative basis, of at least $600,00
Quoted market price of common stock	$ 0.04
Proceed from issuance of common stock	$ 600,000
Common stock issued in pursuant to debenture	2,500,000

XML

Amended and Restated SCMS License Agreement

9 Months Ended

Jul. 31, 2012

License and Development Agreements [Abstract]

Amended and Restated SCMS License Agreement

2.   Amended and Restated SCMS License Agreement

On February 14, 2011, the Company entered into an Amended and Restated technology license agreement (the “Amended and Restated License Agreement”) with The Research Foundation of State University of New York, for and on behalf of the University at Buffalo (the “Foundation”), Donald D. Hickey, M.D. (“Hickey”) and Clas E. Lundgren (“Lundgren”).  The Foundation, Hickey and Lundgren shall be collectively referred to herein as the “Licensor.”  The Amended and Restated License Agreement replaced the technology license agreement entered into by the Company and the Licensor on November 10, 2006, as amended.

Pursuant to the Amended and Restated License Agreement, the Licensor has granted Scivanta the exclusive world-wide rights to develop, manufacture and distribute the SCMS, a minimally invasive two-balloon esophageal catheter system used to monitor cardiac performance.  The term of the Amended and Restated License Agreement ends on the later of (a) the expiration date of the last to expire patent right related to the SCMS, which is currently May 1, 2027, or (b) 17 years from the sale of the first licensed product on a country by country basis.

Under the Amended and Restated License Agreement, Scivanta agreed to pay Hickey $135,000, which was paid or required to be paid as follows:  (a) a cash payment of $30,000 was made to Hickey on June 3, 2011 and (b) a cash payment of $105,000 was due to Hickey on the date that is thirty (30) days after the first commercial sale of a product utilizing the licensed technology, but no later than July 31, 2012.  The Company has not paid the $105,000 due to Hickey and, as a result, the Amended and Restated License Agreement can be placed in default by the Licensor in accordance with the default provisions discussed below.

Scivanta is required to pay the Licensor a royalty of 5% of annual net sales, as defined in the Amended and Restated License Agreement, subject to certain reductions as detailed in the Amended and Restated License Agreement.  Beginning with the first full year of sales of the SCMS in the United States and for two years thereafter, Scivanta is required to pay an annual minimum royalty of $100,000 to the Licensor against which any royalty on net sales paid in the same calendar year for sales in the United States will be credited.  Further, beginning with the first full year of sales of the SCMS outside the United States and for two years thereafter, Scivanta is required to pay an annual minimum royalty of $100,000 to the Licensor against which any royalty on net sales paid in the same calendar year for sales outside the United States will be credited.  The Company is also required to pay the Licensor 25% of all sublicensing revenue, as defined in the Amended and Restated License Agreement, received by the Company in connection with the Company’s sublicense of the rights granted to the Company under the Amended and Restated License Agreement.

The Amended and Restated License Agreement, as amended by the Addendum, also requires Scivanta to use commercially reasonable efforts to develop and market the SCMS within certain timeframes, subject to specified exceptions.  If Scivanta materially fails to perform any covenant, condition or undertaking of the Amended and Restated License Agreement, including the failure to make any payments when due, the Licensor may give written notice of such default to Scivanta.  If Scivanta should fail to cure such default within ninety (90) days of notice of such default, then the Licensor, at its option, may terminate the Amended and Restated License Agreement.  Further, the Amended and Restated License Agreement contains standard provisions regarding indemnification and patent prosecution.

XML

Balance Sheets (USD $)	Jul. 31, 2012	Oct. 31, 2011
Current assets:
Cash	$ 17,994	$ 46,245
Grant receivable		131,979
Prepaid expenses	9,271	6,037
Total current assets	27,265	184,261
Current liabilities:
Accounts payable	227,793	208,912
Accounts payable - related party	66,868	41,302
Accrued expenses	81,835	81,794
Accrued compensation	225,627	225,627
Notes payable	110,412	105,000
Convertible debentures	25,000	75,000
Total current liabilities	737,535	737,635
Convertible debentures	275,000	275,000
Total liabilities	1,012,535	1,012,635
Stockholders' deficiency:
Common stock, $.001 par value; 100,000,000 shares authorized; 31,116,913 and 30,564,543 shares issued and outstanding, respectively	31,117	30,564
Additional paid-in capital	22,343,225	22,264,583
Accumulated deficit	(23,359,612)	(23,123,521)
Total stockholders' deficiency	(985,270)	(828,374)
Total liabilities and stockholders' deficiency	$ 27,265	$ 184,261

XML

Statements of Cash Flows (Parenthetical) (USD $)	9 Months Ended
	Jul. 31, 2012
Statement Of Cash Flows [Abstract]
Shares issued as payment of interest on convertible debentures	552,370
Principal value of Covertible debentures	$ 50,000
Interest on Convertible debentures	$ 3,729
Common stock shares issued as payment for interest due on convertible debentures	500,000

XML

Convertible Debentures (Details) (USD $)			1 Months Ended			1 Months Ended				3 Months Ended		9 Months Ended			3 Months Ended	9 Months Ended
	Jul. 31, 2012	Jan. 04, 2012	Jan. 31, 2012 February 2007 Convertible Debentures [Member]	Feb. 28, 2007 February 2007 Convertible Debentures [Member]	Jan. 11, 2012 February 2007 Convertible Debentures [Member]	Jan. 31, 2012 February 2007 Convertible Debentures [Member] Maximum [Member]	Jan. 31, 2012 February 2007 Convertible Debentures [Member] Minimum [Member]	Jan. 31, 2012 February 2007 Convertible Debentures [Member] Private Placement [Member]	Feb. 28, 2007 February 2007 Convertible Debentures [Member] Private Placement [Member]	Jul. 31, 2012 February 2007 Convertible Debentures [Member] Private Placement [Member]	Jul. 31, 2011 February 2007 Convertible Debentures [Member] Private Placement [Member]	Jul. 31, 2012 February 2007 Convertible Debentures [Member] Private Placement [Member]	Jul. 31, 2011 February 2007 Convertible Debentures [Member] Private Placement [Member]	Feb. 08, 2007 February 2007 Convertible Debentures [Member] Private Placement [Member]	Jul. 31, 2012 May 2011 Convertible Debenture [Member]	Jul. 31, 2012 May 2011 Convertible Debenture [Member]	May 20, 2011 May 2011 Convertible Debenture [Member]
Convertible Debenture (Textual)
Interest rate on convertible debentures		9.30%												8.00%			8.00%
Convertible debt														$ 250,000			$ 100,000
Principal amount of loan from Imperial	5,412	15,867	175,000		50,000
Extension period of debt									2 years
Principal amount of Debentures with extended maturity			25,000
Shares issued for repayment of Convertible Debentures			500,000
Shares issued for payment of accrued interest			52,370
Shares issued for payment of debt, share price			$ 0.10			$ 0.08	$ 0.07
Amended maturity date of debentures				Jan. 31, 2012				Jan. 31, 2014
Second amended maturity date of debentures								Jul. 31, 2012
Loss on conversion of convertible debt			21,750
Interest payable					3,729					24,035		24,035			9,601	9,601
Interest expense										$ 4,033	$ 5,000	$ 12,764	$ 15,000		$ 2,017	$ 6,006

XML

Net Loss Per Common Share (Details)	3 Months Ended		9 Months Ended
	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2012	Jul. 31, 2011
Net Loss Per Common Share (Textual)
Common stock shares issuable upon the exercise of option	2,495,332	2,495,332	2,495,332	2,495,332
Common stock issuable upon the exercise of warrants	930,000	4,046,750	930,000	4,046,750
Common stock shares issuable upon the conversion of convertible debt	4,166,666	4,375,000	4,166,666	4,375,000

XML

Basis of Presentation

9 Months Ended

Jul. 31, 2012

Accounting Policies [Abstract]

Basis of Presentation

1.   Basis of Presentation

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.  The Company has incurred significant recurring operating losses, negative cash flows from operations, has a working capital deficiency and an accumulated deficit of $23,359,612 as of July 31, 2012.  The Company has not paid the $105,000 that was due to Hickey on July 31, 2012 and, as a result, the Amended and Restated License Agreement can be placed in default by the Licensor in accordance with the default provisions of such agreement (see Notes 2 and 4).  The Company also has no lending relationships with commercial banks and is dependent on the completion of a financing involving the private placement of its securities in order to continue operations.  The recent economic slowdown has made financing more difficult to obtain.  These factors raise substantial doubt about the Company’s ability to continue as a going concern.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The Company continues to seek equity and/or debt investors and from time to time engages placement agents to assist the Company in this initiative.  The Company has reduced operating expenses and effective November 1, 2011, each of the Company’s officers agreed to waive the annual base salary due to them and each of the Company’s directors agreed to waive the annual retainer and meeting fees due to them until the Company is able to raise sufficient capital that would provide the Company with the ability to pay cash compensation to its officers and directors.  The Company has also deferred the payment of $200,000 of accrued compensation due to its officers, deferred the payment of $17,000 to its directors and a former director and deferred certain other vendor payments until the Company secures sufficient additional financing.

While the Company is pursuing the opportunities and actions described above, there can be no assurance that it will be successful in its efforts.  If the Company is unable to secure additional capital, it will explore other strategic alternatives, including, but not limited to, the sale of the Company.  Any additional equity financing may result in substantial dilution to our stockholders (see Note 10).

XML

Balance Sheets (Parenthetical) (USD $)	Jul. 31, 2012	Oct. 31, 2011
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	31,116,913	30,564,543
Common stock, shares oustanding	31,116,913	30,564,543

XML

Stockholders' Equity (Tables)

9 Months Ended

Jul. 31, 2012

Stock Option [Member]

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Summary of stock option/warrant transactions for employees and directors under the Equity Incentive Plans

	Stock Option Shares		Weighted Average Exercise Price Per Common Share		Aggregate Intrinsic Value
Outstanding at October 31, 2011		2,495,332	$	0.16	$	5,800
Granted during the period		--		--
Exercised during the period		--		--
Expired during the period		--		--
Outstanding at July 31, 2012		2,495,332	$	0.16	$	700
Exercisable at July 31, 2012		2,495,332	$	0.16	$	700
Exercisable at October 31, 2011		2,328,664	$	0.16	$	5,800

Information with respect to outstanding and exercisable options and warrants

		Stock Options Outstanding						Stock Options Exercisable
Exercise Price		Number of Shares Available Under Outstanding Stock Options		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)		Number of Shares Available for Purchase Under Outstanding Stock Options		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)
$	0.02		35,000	$	0.02		2.4		35,000	$	0.02		2.4
$	0.08		335,000	$	0.08		2.1		335,000	$	0.08		2.1
$	0.14		1,025,332	$	0.14		5.2		1,025,332	$	0.14		5.2
$	0.20		1,100,000	$	0.20		4.5		1,100,000	$	0.20		4.5
			2,495,332	$	0.16		4.4		2,495,332	$	0.16		4.4

Warrant [Member]

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Summary of stock option/warrant transactions for employees and directors under the Equity Incentive Plans

	Warrant Shares			Weighted Average Exercise Price Per Common Share		Aggregate Intrinsic Value
Outstanding at October 31, 2011		4,046,750		$	0.12	$	10,000
Issued during the period		--			--
Exercised during the period		--			--
Expired during the period		(3,116,750	)	$	0.12
Outstanding at July 31, 2012		930,000		$	0.12	$	--
Exercisable at July 31, 2012		930,000		$	0.12	$	--
Exercisable at October 31, 2011		4,046,750		$	0.12	$	10,000

Information with respect to outstanding and exercisable options and warrants

		Warrants Outstanding						Warrants Exercisable
Range of Exercise Prices		Number of Shares Available Under Outstanding Warrants		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)		Number of Shares Available for Purchase Under Outstanding Warrants		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)
$	0.04		200,000	$	0.04		1.8		200,000	$	0.04		1.8
$	0.10 - 0.13		535,000	$	0.12		0.6		535,000	$	0.12		0.6
$	0.20 - 0.25		195,000	$	0.21		1.0		195,000	$	0.21		1.0
			930,000	$	0.12		0.9		930,000	$	0.12		0.9

XML

Document and Entity Information	9 Months Ended
	Jul. 31, 2012	Sep. 17, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	SCIVANTA MEDICAL CORP
Entity Central Index Key	0001093285
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Document Type	10-Q
Document Period End Date	Jul. 31, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		31,116,913

XML

Basis of Presentation (Details) (USD $)			9 Months Ended
	Jul. 31, 2012	Oct. 31, 2011	Jul. 31, 2012 Officers [Member]	Jul. 31, 2012 Directors and Former Director [Member]
Basis of Presentation (Textual)
Deferred payment of accrued compensation			$ 200,000	$ 17,000
Accumulated deficit	(23,359,612)	(23,123,521)
Notes Payable, Related Parties	$ 105,000

XML

Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2012	Jul. 31, 2011
Grant revenue
Operating expenses (income):
Research and development	5,540	6,930	14,430	41,281
General and administrative	62,209	171,411	180,562	534,561
Loss from operations	(67,749)	(178,341)	(194,992)	(575,842)
Interest Expense	(6,217)	(6,821)	(19,349)	(17,141)
Loss on conversion of convertible debentures			(21,750)
Net loss	$ (73,966)	$ (185,162)	$ (236,091)	$ (592,983)
Net loss per common share, basic and diluted	$ 0.00	$ (0.01)	$ (0.01)	$ (0.02)
Weighted average number of common shares outstanding, basic and diluted	31,116,913	30,358,021	30,983,366	30,071,869

XML

Stock-Based Compensation

9 Months Ended

Jul. 31, 2012

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Stock-Based Compensation

6.   Stock-Based Compensation

The Company accounts for stock-based payments to employees in accordance with Accounting Standards Codification 718, “Stock Compensation” (“ASC 718”).  During the three and nine months ended July 31, 2012, the Company recorded employee stock-based compensation expense of $0 and $3,716, respectively, which have been included in general and administrative expense.  During the three and nine months ended July 31, 2011, the Company recorded employee stock-based compensation expense of $4,221 and $16,782, respectively,  which have been included in general and administrative expense.

XML

Convertible Debentures

9 Months Ended

Jul. 31, 2012

Convertible Debentures [Abstract]

Convertible Debentures

5.   Convertible Debentures

February 2007 Convertible Debentures

On February 8, 2007, the Company closed on a private placement of 8% convertible debentures dated February 1, 2007 totaling $250,000 (the “February 2007 Debentures”).  In January 2010, the holders agreed to amend the February 2007 Debentures.  Pursuant to this amendment, the holders agreed to a new maturity date of January 31, 2012, extending the term of the February 2007 Debentures for an additional two year period.

On January 11, 2012, the Company issued 500,000 shares of common stock at $0.10 per share as full payment of $50,000 of outstanding principal on certain February 2007 Debentures and 52,370 shares of common stock at per share prices ranging between $0.07 and $0.08 as full payment of $3,729 of accrued and unpaid interest related to those February 2007 Debentures.  Due to the reduction in the conversion price, the Company recorded a loss on conversion of these February 2007 Debentures of $21,750.

Effective January 31, 2012, certain holders of February 2007 Debentures with an aggregate outstanding principal amount of $175,000, agreed to amend such February 2007 Debentures by extending the maturity date to January 31, 2014.  In addition, effective January 31, 2012, a holder of a February 2007 Debenture with an outstanding principal amount of $25,000 agreed to amend his February 2007 Debenture by extending the maturity date to July 31, 2012.  The Company has not made payment on this February 2007 Debenture and as a result, such obligation can be placed in default by the holder.

For the three and nine months ended July 31, 2012, the Company recorded a total of $4,033 and $12,764, respectively, of interest expense related to the February 2007 Debentures.  For the three and nine months ended July 31, 2011, the Company recorded a total of $5,000 and $15,000, respectively, of interest expense related to the February 2007 Debentures.  As of July 31, 2012, $24,035 of interest due on the February 2007 Debentures was accrued and is included as a component of accrued expenses.

May 2011 Convertible Debenture

On May 20, 2011, the Company issued an 8% convertible debenture in the amount of $100,000 to an institutional investor (the “May 2011 Debenture”).  For the three and nine months ended July 31, 2012, the Company recorded a total of $2,017 and $6,006 of interest expense related to the May 2011 Debenture.  As of July 31, 2012, $9,601 of interest due on the May 2011 Debenture was accrued and is included as a component of accrued expenses.

XML

Stock-Based Compensation (Details) (USD $)	3 Months Ended		9 Months Ended
	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2012	Jul. 31, 2011
Stock Based Compensation (Textual)
Share-based compensation expense	$ 0	$ 4,221	$ 3,716	$ 16,782

XML

Amended and Restated SCMS License Agreement (Details) (USD $)	9 Months Ended
	Jul. 31, 2012	Jun. 03, 2011
Amended and Restated SCMS License Agreement (Textual)
Term of amended and restated license agreement, Description	Later of (a) the expiration date of the last to expire patent right related to the SCMS, which is currently May 1, 2027, or (b) 17 years from the sale of the first licensed product on a country by country basis.
License costs under the amended and restated license agreement	$ 135,000
Amended and restated license agreement payment, Description	a) A cash payment of $30,000 was made to Hickey on June 3, 2011 and (b) a cash payment of $105,000 is due to Hickey on the date that is thirty (30) days after the first commercial sale of a product utilizing the licensed technology, but no later than July 31, 2012.
Notes payable due to Hickey	105,000
Cash payment for licensing agreement		30,000
Royalty payment, Description	5% of annual net sales.
Minimum royalty payment for first full year of sales of the SCMS in the United States and for two years thereafter	100,000
Minimum royalty payment for first full year of sales of the SCMS outside the United States and for two years thereafter	$ 100,000
Percentage of sublicensing revenue require to pay licensor under the Amended and Restated License Agreement	25.00%
Notice period incase of default in perform any covenant of the Amended and Restated License Agreement	90 days

XML

Subsequent Events

9 Months Ended

Jul. 31, 2012

Subsequent Events [Abstract]

Subsequent Events

10. Subsequent Events

On August 15, 2012, the Company issued an 8% convertible debenture to an institutional investor (the “August 2012 Debenture”).  The gross proceeds received in connection with this private placement were $100,000.  The August 2012 Debenture has a three year term maturing on August 15, 2015 and bears interest at a rate of 8% per annum.  Interest is payable in annual installments, beginning on August 15, 2013, in cash or, at the option of the Company, in shares of the Company’s common stock.  If the Company elects to pay the interest in shares of the Company’s common stock, the number of shares issued as payment will be equal to the quotient of the unpaid interest divided by the market price of the Company’s common stock as defined in the August 2012 Debenture.

The entire principal amount of the August 2012 Debenture is convertible at any time into shares of the Company’s common stock at the option of the holder at a conversion price of $0.04 per share.  In addition, at the option of the Company and subject to certain restrictions provided in the August 2012 Debenture, the entire principal amount of the August 2012 Debenture is convertible into shares of the Company’s common stock at a conversion price of $0.04 per share upon the occurrence of: (a) a merger or acquisition of the Company or (b) the closing of a financing involving the Company’s common stock that results in gross proceeds to the Company, on a cumulative basis, of at least $600,000.  The quoted market price of the Company’s common stock as of August 15, 2012 was $0.04 per share.

An aggregate amount of 2,500,000 shares of the Company’s common stock can be issued pursuant to the August 2012 Debenture. The Company will use the proceeds received in this private placement for working capital purposes.

XML

Net Loss Per Common Share

9 Months Ended

Jul. 31, 2012

Earnings Per Share [Abstract]

Net Loss Per Common Share

7.   Net Loss Per Common Share

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period.  Diluted earnings per share reflect, in periods in which they have a dilutive effect, the impact of common shares issuable upon exercise of stock options and warrants and conversion of convertible debt that are not deemed to be anti-dilutive.  The dilutive effect of the outstanding stock options and warrants is computed using the treasury stock method.

For the three and nine months ended July 31, 2012, diluted net loss per share did not include the effect of 2,495,332 shares of common stock issuable upon the exercise of outstanding options, 930,000 shares of common stock issuable upon the exercise of outstanding warrants and 4,166,666 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive.

For the three and nine months ended July 31, 2011, diluted net loss per share did not include the effect of 2,495,332 shares of common stock issuable upon the exercise of outstanding options, 4,046,750 shares of common stock issuable upon the exercise of outstanding warrants and 4,375,000 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive.

XML

Stockholders' Equity

9 Months Ended

Jul. 31, 2012

Equity [Abstract]

Stockholders’ Equity

8.   Stockholders’ Equity

Stock Option Plans

The Company currently has two stock option plans in place:  the 2002 Equity Incentive Plan and the 2007 Equity Incentive Plan (collectively, the “Equity Incentive Plans”).  The 2002 Equity Incentive Plan was approved by the stockholders on July 5, 2002.  The aggregate number of shares of common stock which could have been awarded under the 2002 Equity Incentive Plan was 2,000,000.  As of July 31, 2012, options to purchase 1,470,000 shares of the Company’s common stock were outstanding under the 2002 Equity Incentive Plan.  As a result of the adoption of the Company’s 2007 Equity Incentive Plan, no further awards are permitted under the 2002 Equity Incentive Plan.

On May 31, 2007, the stockholders approved the Company’s 2007 Equity Incentive Plan.  The 2007 Equity Incentive Plan was placed into effect in order to encourage and enable employees and directors of the Company to acquire or increase their holdings of the Company’s common stock and to promote these individual’s interests in the Company thereby enhancing the efficiency, soundness, profitability, growth and stockholder value of the Company.  The 2007 Equity Incentive Plan provides for awards in the form of restricted shares, incentive stock options, non-qualified stock options and stock appreciation rights.  The aggregate number of shares of common stock which may be awarded under the 2007 Equity Incentive Plan is 3,000,000, subject to adjustment as provided in the 2007 Equity Incentive Plan.  As of July 31, 2012, options to purchase 1,025,332 shares of the Company’s common stock were outstanding under the 2007 Equity Incentive Plan and up to 1,974,668 shares of the Company’s common stock remain available for awards under the 2007 Equity Incentive Plan.

Stock option awards under the Equity Incentive Plans were granted at prices as determined by the Company’s compensation committee, but such prices were not less than the fair market value of the Company's common stock on the date of grant.  Stock options granted and outstanding include only non-qualified options and vest over a period of up to five years and have a maximum term of ten years from the date of grant.

A summary of stock option transactions for employees and directors under the Equity Incentive Plans during the nine months ended July 31, 2012 is as follows:

	Stock Option Shares		Weighted Average Exercise Price Per Common Share		Aggregate Intrinsic Value
Outstanding at October 31, 2011		2,495,332	$	0.16	$	5,800
Granted during the period		--		--
Exercised during the period		--		--
Expired during the period		--		--
Outstanding at July 31, 2012		2,495,332	$	0.16	$	700
Exercisable at July 31, 2012		2,495,332	$	0.16	$	700
Exercisable at October 31, 2011		2,328,664	$	0.16	$	5,800

Information with respect to outstanding options and options exercisable as of July 31, 2012 that were granted to employees is as follows:

		Stock Options Outstanding						Stock Options Exercisable
Exercise Price		Number of Shares Available Under Outstanding Stock Options		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)		Number of Shares Available for Purchase Under Outstanding Stock Options		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)
$	0.02		35,000	$	0.02		2.4		35,000	$	0.02		2.4
$	0.08		335,000	$	0.08		2.1		335,000	$	0.08		2.1
$	0.14		1,025,332	$	0.14		5.2		1,025,332	$	0.14		5.2
$	0.20		1,100,000	$	0.20		4.5		1,100,000	$	0.20		4.5
			2,495,332	$	0.16		4.4		2,495,332	$	0.16		4.4

Warrants to Purchase Common Stock

A summary of warrant transactions during the nine months ended July 31, 2012 is as follows:

	Warrant Shares			Weighted Average Exercise Price Per Common Share		Aggregate Intrinsic Value
Outstanding at October 31, 2011		4,046,750		$	0.12	$	10,000
Issued during the period		--			--
Exercised during the period		--			--
Expired during the period		(3,116,750	)	$	0.12
Outstanding at July 31, 2012		930,000		$	0.12	$	--
Exercisable at July 31, 2012		930,000		$	0.12	$	--
Exercisable at October 31, 2011		4,046,750		$	0.12	$	10,000

Information with respect to outstanding warrants and warrants exercisable at July 31, 2012 is as follows:

		Warrants Outstanding						Warrants Exercisable
Range of Exercise Prices		Number of Shares Available Under Outstanding Warrants		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)		Number of Shares Available for Purchase Under Outstanding Warrants		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)
$	0.04		200,000	$	0.04		1.8		200,000	$	0.04		1.8
$	0.10 - 0.13		535,000	$	0.12		0.6		535,000	$	0.12		0.6
$	0.20 - 0.25		195,000	$	0.21		1.0		195,000	$	0.21		1.0
			930,000	$	0.12		0.9		930,000	$	0.12		0.9

XML

Stock-Based Compensation (Policies)

9 Months Ended

Jul. 31, 2012

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Stock Compensation

The Company accounts for stock-based payments to employees in accordance with Accounting Standards Codification 718, “Stock Compensation” (“ASC 718”)

XML

Notes Payable (Details) (USD $)	3 Months Ended	9 Months Ended
	Jul. 31, 2012	Jul. 31, 2012	Jan. 04, 2012
Notes Payable (Textual)
Notes payable due to Hickey	$ 105,000	$ 105,000
Principal amount of loan from Imperial	5,412	5,412	15,867
Interest rate on loan from Imperial			9.30%
Monthly payments for loan		1,832
Number of periodic payments		9
Interest Expense related to financing agreement	$ 167	$ 579

XML

Stockholders' Equity (Details 1) (Stock Option [Member], USD $)	9 Months Ended
	Jul. 31, 2012	Oct. 31, 2011
Information with respect to outstanding and exercisable options and warrants
Stock Options/ Warrants Outstanding, Number of Shares Available Under Outstanding Stock Options	2,495,332
Stock Options/ Warrants Outstanding, Weighted Average Exercise Price Per Common Share	$ 0.16
Stock Options/ Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	4 years 4 months 24 days
Stock Options/ Warrants Exercisable, Number of Shares Available for Purchase Under Outstanding Stock Options	2,495,332	2,328,664
Stock Options/ Warrants Exercisable, Weighted Average Exercise Price Per Common Share	$ 0.16	$ 0.16
Stock Options/ Warrants Exercisable, Weighted Average Remaining Contractual Life (Years)	4 years 4 months 24 days
0.02 [Member]
Information with respect to outstanding and exercisable options and warrants
Exercise Prices	$ 0.02
Stock Options/ Warrants Outstanding, Number of Shares Available Under Outstanding Stock Options	35,000
Stock Options/ Warrants Outstanding, Weighted Average Exercise Price Per Common Share	$ 0.02
Stock Options/ Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 4 months 24 days
Stock Options/ Warrants Exercisable, Number of Shares Available for Purchase Under Outstanding Stock Options	35,000
Stock Options/ Warrants Exercisable, Weighted Average Exercise Price Per Common Share	$ 0.02
Stock Options/ Warrants Exercisable, Weighted Average Remaining Contractual Life (Years)	2 years 4 months 24 days
0.08 [Member]
Information with respect to outstanding and exercisable options and warrants
Exercise Prices	$ 0.08
Stock Options/ Warrants Outstanding, Number of Shares Available Under Outstanding Stock Options	335,000
Stock Options/ Warrants Outstanding, Weighted Average Exercise Price Per Common Share	$ 0.08
Stock Options/ Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 1 month 6 days
Stock Options/ Warrants Exercisable, Number of Shares Available for Purchase Under Outstanding Stock Options	335,000
Stock Options/ Warrants Exercisable, Weighted Average Exercise Price Per Common Share	$ 0.08
Stock Options/ Warrants Exercisable, Weighted Average Remaining Contractual Life (Years)	2 years 1 month 6 days
0.14 [Member]
Information with respect to outstanding and exercisable options and warrants
Exercise Prices	$ 0.14
Stock Options/ Warrants Outstanding, Number of Shares Available Under Outstanding Stock Options	1,025,332
Stock Options/ Warrants Outstanding, Weighted Average Exercise Price Per Common Share	$ 0.14
Stock Options/ Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	5 years 2 months 12 days
Stock Options/ Warrants Exercisable, Number of Shares Available for Purchase Under Outstanding Stock Options	1,025,332
Stock Options/ Warrants Exercisable, Weighted Average Exercise Price Per Common Share	$ 0.14
Stock Options/ Warrants Exercisable, Weighted Average Remaining Contractual Life (Years)	5 years 2 months 12 days
0.20 [Member]
Information with respect to outstanding and exercisable options and warrants
Exercise Prices	$ 0.20
Stock Options/ Warrants Outstanding, Number of Shares Available Under Outstanding Stock Options	1,100,000
Stock Options/ Warrants Outstanding, Weighted Average Exercise Price Per Common Share	$ 0.20
Stock Options/ Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	4 years 6 months
Stock Options/ Warrants Exercisable, Number of Shares Available for Purchase Under Outstanding Stock Options	1,100,000
Stock Options/ Warrants Exercisable, Weighted Average Exercise Price Per Common Share	$ 0.20
Stock Options/ Warrants Exercisable, Weighted Average Remaining Contractual Life (Years)	4 years 6 months

XML

Statements of Cash Flows (USD $)	9 Months Ended
	Jul. 31, 2012	Jul. 31, 2011
Cash flows from operating activities:
Net loss	$ (236,091)	$ (592,983)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation expense	3,716	16,782
License fees		26,562
Loss on conversion of convertible debentures	21,750
Changes in operating assets and liabilities:
Grant receivable	131,979	112,500
Prepaid expenses	12,633	22,847
Accounts payable	18,881	45,426
Accounts payable - related party	25,566	(5,044)
Accrued expenses	3,770	5,457
Accrued compensation		299,929
Net cash used in operating activities	(17,796)	(68,524)
Cash flows from financing activities:
Proceeds from sale of common stock, net of offering costs		22,125
Proceeds from issuance of convertible debenture		100,000
Repayment of notes payable	(10,455)	(42,248)
Refund of proceeds from deposit on stock purchase		(100,000)
Restricted cash – stock purchase		100,000
Net cash (used in) provided by financing activities	(10,455)	79,877
(Decrease) increase in cash	(28,251)	11,353
Cash - beginning of period	46,245	81,365
Cash - end of period	17,994	92,718
Supplemental disclosure of cash flow information:
Cash paid for interest	579	563
Noncash financing activities:
Issuance of 552,370 shares of common stock as payment of $50,000 of principal and $3,729 of interest due on convertible debentures	53,729
Issuance of note payable as payment for insurance premium	15,867	15,867
Issuance of 500,000 shares of common stock as payment for interest due on convertible debentures		$ 20,000

XML

Notes Payable

9 Months Ended

Jul. 31, 2012

Debt Disclosure [Abstract]

Notes Payable

4.   Notes Payable

Note Payable – Hickey

Under the Amended and Restated License Agreement (see Note 2), a cash payment of $105,000 was due to Hickey on July 31, 2012.  The Company has not paid the $105,000 due to Hickey and, as a result, the Amended and Restated License Agreement can be placed in default by the Licensor in accordance with the default provisions of such agreement.  The Company recorded the $105,000 due to Hickey as a component of notes payable.

Note Payable – Insurance

On January 4, 2012, the Company entered into a finance agreement with Imperial Credit Corporation (“Imperial”).  Pursuant to the terms of this finance agreement, Imperial loaned the Company the principal amount of $15,867, which amount would accrue interest at a rate of 9.3% per annum, in order to partially fund the payment of the premium of the Company’s director and officer liability insurance.  The finance agreement requires the Company to make nine monthly payments of $1,832, including interest, with the first payment due on January 31, 2012.  For the three and nine months ended July 31, 2012, the Company recorded a total of $167 and $579, respectively, of interest expense related to this finance agreement.  As of July 31, 2012, the outstanding principal balance related to this finance agreement was $5,412, which is recorded as a component of notes payable.

XML

Stockholders' Equity (Details 2) (Warrant [Member], USD $)	9 Months Ended
	Jul. 31, 2012
Warrant [Member]
Summary of warrant transactions
Stock Option/Warrants Shares, Outstanding Beginning Balance	4,046,750
Weighted Average Exercise Price Per Common Share/Warrants, Outstanding Beginning Balance	$ 0.12
Aggregate Intrinsic Value, Outstanding Stock Option/Warrants beginning balance	$ 10,000
Stock Option/Warrants, Granted during the period
Weighted Average Exercise Price Per Common Share/Warrants, Granted during the period
Stock Option/Warrants, Exercised during the period
Weighted Average Exercise Price Per Common Share/Warrants, Exercised during the period
Stock Option/Warrants, Expired during the period	(3,116,750)
Weighted Average Exercise Price Per Common Share/Warrants, Expired during the period	$ 0.12
Stock Option/Warrants, Outstanding at July 31, 2012	930,000
Weighted Average Exercise Price Per Common Share/Warrants, Outstanding at July 31, 2012	$ 0.12
Aggregate Intrinsic Value, Outstanding Stock Option/Warrants at July 31, 2012
Stock Option Shares/Warrants, Exercisable at July 31, 2012	930,000
Weighted Average Exercise Price Per Common Share/Warrants, Exercisable at July 31, 2012	$ 0.12
Aggregate Intrinsic Value, Stock Option/Warrants Exercisable at July 31, 2012
Stock Option/Warrants, Exercisable at October 31, 2011	4,046,750
Weighted Average Exercise Price Per Common Share/Warrant, Exercisable at October 31, 2011	$ 0.12
Aggregate Intrinsic Value, Stock Option/Warrants Exercisable at October 31, 2011	$ 10,000

XML

Related Party Transactions (Details) (USD $)	3 Months Ended		9 Months Ended
	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2012	Jul. 31, 2011
Related Party Transactions (Textual)
Area of office space (square feet)			2,000
Sublease agreement term			60 days
Monthly rental fee			$ 5,000
Sublease agreement expenses	17,730	16,005	54,297	51,913
Rent expenses included in accounts payable - related party	65,000		65,000
Other expenses included in accounts payable - related party	$ 1,868		$ 1,868